 | | Vol. 8.47 – 16 December, 2020 |
| |
|
|
| Scientists report the results of the Genetics Of Mortality In Critical Care genome-wide association study in 2244 critically ill Covid-19 patients from 208 UK intensive care units.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels.
[Cell] |
|
|
|
| Researchers performed viral whole-genome sequencing on 157 matched SARS-CoV-2-positive patient specimens and synthetic RNA controls, enabling rigorous evaluation of analytical performance.
[Nature Communications] |
|
|
|
| The authors showed analysis of autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter-patient and intra-patient heterogeneity of pulmonary virus infection.
[Nature Communications] |
|
|
|
| Scientists solved x-ray crystal structures of Mpro in complex with calpain inhibitors II and XII and three analogs of GC-376. The structure of Mpro with calpain inhibitor II confirmed that the S1 pocket could accommodate a hydrophobic methionine side chain, challenging the idea that a hydrophilic residue was necessary at this position.
[Science Advances] |
|
|
|
| Investigators studied the immune responses in COVID-19 and influenza patients. Compared to patients with influenza, patients with COVID-19 exhibited largely equivalent lymphocyte counts, fewer monocytes, and lower surface human leukocyte antigen-class II expression on selected monocyte populations.
[Science Advances] |
|
|
|
| Researchers demonstrated that ORF3a of the COVID-19 virus SARS-CoV-2 inhibits autophagy activity by blocking fusion of autophagosomes/amphisomes with lysosomes.
[Developmental Cell] |
|
|
|
| Scientists revealed transcriptomic profiles indicative of defective antigen presentation and interferon responsiveness in monocytes from acute respiratory distress syndrome patients, which contrasts with higher responsiveness to interferon signaling in lymphocytes.
[Cell Reports] |
|
|
|
| The authors studied the whole-blood transcriptomic host response to SARS-CoV-2 using RNAseq from 24 healthy controls and 62 prospectively enrolled patients with COVID-19.
[iScience] |
|
|
|
| Protein-protein docking was utilized for identifying the critical epitopes in CD147, CD209 and CD299 which are involved in the binding with SARS-CoV-2 Spike receptor binding domain.
[Heliyon] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists investigated the impact of preexisting immunity on generation of protective antibody responses to conserved viral epitopes upon influenza virus infection and vaccination in humans.
[Science Translational Medicine] |
|
|
|
| Researchers characterized the early steps of infection in an ex vivo infection model of the human decidua, the puerperal fever portal of entry.
[Journal of Clinical Investigation] |
|
|
|
| Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation was significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
[Cell Reports] |
|
|
|
|
| By analogy, SARS-CoV-2 is a vector that initially homes to pulmonary stem cells that preferentially express the ACE2 receptor, thus potentially incurring similarly robust pathological consequences.
[Laboratory Investigation] |
|
|
|
| The authors discuss the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
[Gene Therapy] |
|
|
|
|
| Arch Biopartners, Inc. announced that the Government of Canada has awarded a contribution of up to $6.7 million from the department of Innovation, Science and Economic Development to support the Phase II development of Metablok, the company’s therapeutic drug candidate to prevent organ inflammation and injury in patients hospitalized with COVID-19.
[Arch Biopartners, Inc. (Globe Newswire, Inc.)] |
|
|
|
| Valneva SE announced the initiation of a Phase I/II clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
[Valneva SE] |
|
|
|
| RedHill Biopharma Ltd. announced promising preliminary results from a preclinical study within which opaganib, a novel, orally administered sphingosine kinase 2 selective inhibitor, demonstrating a reduction of thrombosis in an acute respiratory distress syndrome (ARDS) – a preclinical animal model designed to measure thrombotic risks.
[RedHill Biopharma Ltd.] |
|
|
|
|
| January 7 – 8, 2021
Virtual |
|
|
|
|
|
| | University of Minnesota Medical School – Minneapolis, Minnesota, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University of California Irvine – Irvine, California, United States |
|
|
|
| | University of Nantes – Nantes, France |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
